We have diligently pursued this project for many years to reach the Phase 2 trial stage. The latest data is from 10 patients, with the next readout scheduled for January. Our share register is as follows:
Institutions: 86.6%
Private Companies: 4.93%
Individual Insiders: 3.64%
General Public: 4.8%
For additional context, please refer to the following relevant links from a company operating in the same field.
https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/pharma-finance-and-investment-news/asceneuron-secures-100m-funding-to-advance-therapeutics-in-neurodegenerative-diseases/
https://asceneuron.com/
We have diligently pursued this project for many years to reach...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.2¢ | $36.94K | 11.98M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 741680 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 152086887 | 65 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |